Marc A. Rodwin
Pharmacology, Toxicology and Pharmaceutics · Indiana University
Publications
152
Citations
1,350
Est. group size
—
Recurring co-author estimate
Active years
45
Publishing since 1982
Marc A. Rodwin studies the policies, laws, and economics that govern pharmaceutical pricing and the healthcare system, with a strong focus on how drug prices are set and controlled. Much of the work compares the United States with European countries (the UK, France, and Germany) and examines issues like Medicare drug price negotiation, conflicts of interest among clinicians, and corruption in the pharmaceutical industry. The research sits at the intersection of health policy, law, and drug economics rather than laboratory pharmacology.
Publication activity has been uneven over the past decade, with peak output around 2019 and 2021 and a lower, steadier rate of about two papers per year more recently.
Generated by claude-opus-4-8 from public bibliographic data · Jul 11, 2026
- Probing the Prevalence of Pharmaceutical Corruption
SSRN Electronic Journal · 2026
- Negotiating Medicare Drug Prices: A New Attempt to Control Purchase Prices
The Journal of Law Medicine & Ethics · 2025
- Exit and Voice in American Health Care
University of Michigan Journal of Law Reform · 2025
- Pharmaceutical pricing strategies in the United States
Elsevier eBooks · 2025
- Clinician Conflicts of Interest at the Cleveland Clinic: The Context and Functions of Disclosure Policy and What Remains Unknown
The Journal of Law Medicine & Ethics · 2024
- How Will Medicare Negotiate Drug Prices, And What Impact Will It Have?
Forefront Group · 2024
- Commentary: Clinician Conflicts of Interest at the Cleveland Clinic: The Context and Functions of Disclosure Policy and What Remains Unknown
SSRN Electronic Journal · 2024
- Negotiating Medicare Drug Prices: A New Attempt to Control Spending
SSRN Electronic Journal · 2024
- The FDA’s Dueling Narratives: Protector Versus Obstacle
Forefront Group · 2023
- Assessing US Pharmaceutical Policy and Pricing Reform Legislation in Light of European Price and Cost Control Strategies
Journal of Health Politics Policy and Law · 2022
- The No Surprises Act: A Conservative Band-Aid to Protect Business as Usual
International Journal of Social Determinants of Health and Health Services · 2022
- How the United Kingdom Controls Pharmaceutical Prices and Spending: Learning From Its Experience
International Journal of Health Services · 2021
- Common Pharmaceutical Price and Cost Controls in the United Kingdom, France, and Germany: Lessons for the United States
International Journal of Health Services · 2021
- German Pharmaceutical Pricing: Lessons for the United States
International Journal of Health Services · 2021
- The use of ‘added benefit’ to determine the price of new anti-cancer drugs in France, 2004–2017
European Journal of Cancer · 2021
- International Journal of Health Services×4
- SSRN Electronic Journal×4
- Elsevier eBooks×3
- BMJ×2
- European Journal of Cancer×2
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 11, 2026.
Claim or correct this profile